Development and validation of a multimodality radiomics-based nomogram for predicting HER2 expression status in invasive breast cancer - Top-Institutions - MDSpire

Development and validation of a multimodality radiomics-based nomogram for predicting HER2 expression status in invasive breast cancer

By
Xianwei Yang
Xiaoling Liu
Shenghong Wan
Yilin Luo
Mengjun Shen
Xin Liao
July 14, 2026

Frontiers In Oncology

Share

Top Institutions in Oncology

Brief introduction explaining scope and methodology.

#1

Affiliated Hospital of Guizhou Medical University

Guiyang, Guizhou
Key Differentiators
- Oncology
#2

Heidelberg University Medical Faculty

Heidelberg, Baden-Württemberg
Key Differentiators
- Oncology
#3

Harbin Medical University Cancer Hospital

Harbin, Heilongjiang
Key Differentiators
- Oncology
#4

FHHMU

Unknown, Unknown
Key Differentiators
- Oncology
#5

Hospital Clínico Universitario de Valencia

Valencia, Valencia
Key Differentiators
- Oncology

Original Source(s)

Frontiers In Oncology

Development and validation of a multimodality radiomics-based nomogram for predicting HER2 expression status in invasive breast cancer

by Xianwei Yang, Xiaoling Liu, Shenghong Wan, Yilin Luo, Mengjun Shen, Xin Liao
July 14, 2026

Related Content

Frontiers In Oncology

Case Report: Aplastic anemia associated with parvovirus B19 infection following neoadjuvant pembrolizumab-based chemoimmunotherapy for triple-negative breast cancer

Frontiers In Oncology

Potential profile analysis of return-to-work readiness and self-efficacy in postoperative breast cancer patients who have returned to work

by Qiu Huo, Shiqi Li, Yunxia Pu, Ying Huang, Huizhuo Deng
July 3, 2026

Frontiers In Oncology

Cancer-related microangiopathic hemolytic anemia (CR-MAHA) in a metastatic breast cancer patient with a germ-line ATM single nucleotide variant and an ESR1 fusion variant: insights from a case report on early diagnosis and improved outcomes